

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau




D4

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : <b>A61M 29/02</b>		A2	(11) International Publication Number: <b>WO 00/32267</b>
			(43) International Publication Date: <b>8 June 2000 (08.06.00)</b>
(21) International Application Number: <b>PCT/US99/28544</b>			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: <b>3 December 1999 (03.12.99)</b>			
(30) Priority Data: <b>09/204,254</b> <b>3 December 1998 (03.12.98)</b> <b>US</b>			
(71) Applicants: <b>SCIMED LIFE SYSTEMS, INC. [US/US]; One Scimed Place, Maple Grove, MN 55311-1566 (US). ST. ELIZABETH'S MEDICAL CENTER, INC. [US/US]; 736 Cambridge Street, Boston, MA 02135 (US).</b>			
(72) Inventors: <b>PALASIS, Maria; 65 Martin Road, Wellesley, MA 02181 (US). WALSH, Kenneth; 207 Judy Farm Road, Carlisle, MA 01741 (US).</b>			
(74) Agents: <b>CAVANAUGH, David, L. et al.; Kenyon &amp; Kenyon, Suite 700, 1500 K Street, N.W., Washington, DC 20005 (US).</b>			Published <i>Without international search report and to be republished upon receipt of that report.</i>

(54) Title: **HIGH EFFICIENCY LOCAL DRUG DELIVERY**



(57) Abstract

A method of site-specifically delivering a therapeutic agent to a target location within a body cavity, vasculature or tissue. The method comprises the steps of providing a medical device having a substantially saturated solution of therapeutic agent associated therewith; introducing the medical device into the body cavity, vasculature or tissue; releasing a volume of the solution of therapeutic agent from the medical device at the target location at a pressure of from about 0 to about 5 atmospheres for a time of up to about 5 minutes; and withdrawing the medical device from the body cavity, vasculature or tissue. In another aspect, the present invention includes a system for delivering a therapeutic agent to a body cavity, vasculature or tissue, comprising a medical device having a substantially saturated solution of the therapeutic agent associated therewith.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## HIGH EFFICIENCY LOCAL DRUG DELIVERY

This is a continuation-in-part of application number 09/106,855 filed 30 June 1998, now abandoned.

5

### FIELD OF THE INVENTION

The present invention relates to the site-specific delivery of therapeutic agents to target locations within body cavities, vasculatures, or tissues.

10

### BACKGROUND

The treatment of disease such as vascular disease by local pharmacotherapy presents a means of delivering therapeutic drug doses to target tissues while minimizing systemic side effects. Recently, for example, the local delivery of gene constructs to effect vascular response has gained increased interest. Gene transfection of vascular smooth muscle cells in vivo, however, remains a problem due to low transfer efficiency attributed in part to inefficient local delivery devices and to the barrier properties of the vessel wall.

15

20

As an example of localized delivery of therapeutic agents, in vivo adenoviral gene transfer has been accomplished with the use of site-specific delivery catheters. Independent of the local delivery device used, most studies have delivered viral doses ranging from  $1 \times 10^9$  to  $1 \times 10^{10}$  pfu/ml over extended

25

delivery times of 20 minutes or longer, and typically in delivery volumes of 1 ml or more. Although these conditions are widely used, the lack of optimization studies with local delivery devices suggests that delivery conditions are not necessarily optimal. Moreover, conventional localized techniques are often invasive in that they typically involve side branch ligation, long delivery times, and when the delivery device is an expandable device such as a balloon catheter, these techniques usually are associated with high pressures to accomplish drug delivery. Localized delivery techniques making use of long delivery times and high pressures and volumes often result in tissue damage, ischemia and other problems. Attempts have been made to reduce the delivery time from an infusion based device using a polymer carrier such as Poloxamer (BASF Corporation), whereby delivery times are reduced from 30 minutes to 5 minutes. The clinical utility of this approach, however, remains uncertain.

20

#### SUMMARY OF THE INVENTION

In one aspect, the present invention includes a method of site-specifically delivering a therapeutic agent to a target location within a body cavity, vasculature or tissue. The method comprises the steps of providing a medical device having a substantially saturated solution of therapeutic agent associated therewith; introducing the medical device into the body cavity, vasculature or tissue; releasing a volume of the solution of therapeutic agent from the medical device at the target location at a pressure of from about 0 to about 5 atmospheres for a time of up to about 5 minutes; and withdrawing the medical device from the body cavity, vasculature or tissue.

In another aspect, the present invention includes a system for delivering a therapeutic agent to

a body cavity, vasculature or tissue, comprising a medical device having a substantially saturated solution of the therapeutic agent associated therewith.

5    BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows a medical device in accordance with an embodiment of the present invention.

Fig. 2 shows a cross-section of an infusion catheter used in accordance with an embodiment of the present invention.

Fig. 3 shows a stent used in accordance with an embodiment of the present invention.

Fig. 4 shows a medical device being positioned to a target location within a body lumen, in accordance with an embodiment of the present invention.

DETAILED DESCRIPTION

The present invention overcomes the deficiencies of conventional localized drug delivery techniques by providing a site-specific, minimally-invasive method of delivering therapeutic agents to tissue. The method of the present invention advantageously makes use of low delivery pressures and short delivery durations to provide for the quick and safe localized delivery of therapeutic agents to any suitable lumen, cavity, or tissue in the body such as, for example, blood vessels, heart tissue, and locations within the gastrointestinal tract and urological and gynecological systems. The terms "drug" and "therapeutic agent" are used interchangeably herein and include pharmaceutically active compounds, nucleic acids with and without carrier vectors such as lipids, compacting agents (such as histones), virus, polymers, proteins, and the like, with or without targeting sequences.

In the localized delivery of therapeutic

agents, pressure-driven convection and concentration-driven diffusion are the two predominant transport mechanisms in the target tissue. The relative importance of these mechanisms, however, has previously  
5 not been well-understood. Convective flow is defined as fluid flow through a solvent space due to a pressure difference acting across a region of tissue. Convective solute transport occurs when dissolved solutes are carried along with the fluid flow.  
10 Although small molecules are generally easily convected with the fluid flow, a sieving effect by the tissue tends to retard large molecules. In contrast to convective transport, molecular diffusion is defined as solute transport from regions of high concentration to  
15 regions of low concentration due to random molecular motions. Transport due to molecular diffusion is directly proportional to an applied concentration gradient.

The inventors have surprisingly discovered  
20 that under appropriate conditions, therapeutic agents are transported into tissue in a manner consistent with molecular diffusion. Correspondingly, the inventors have surprisingly found that variations in applied pressure during localized drug administration has no  
25 significant effect on the transport of drug agents or other therapeutic agents into target tissue. The present invention makes use of this finding by providing for drug delivery based on the principles of concentration-driven diffusion. Delivery of  
30 therapeutic agents is thus achieved by controlling the concentration of therapeutic agent at a target location, rather than relying on pressure-driven processes.

In one aspect, the present invention includes  
35 a method of site-specifically delivering a therapeutic agent to a target location within a body cavity,

vasculature or tissue of a mammal. The method comprises the steps of providing a medical device having a substantially saturated solution of therapeutic agent associated therewith; introducing the  
5 medical device into the body cavity, vasculature, or tissue sought to be treated; releasing the solution of therapeutic agent from the medical device at the target location at a pressure of from about 0 to about 5 atmospheres; and withdrawing the medical device from  
10 the target location within about 5 minutes from the time of releasing the solution from the medical device.

To achieve high efficiency drug delivery by concentration-driven molecular diffusion, the therapeutic agent is incorporated into the medical  
15 device as a substantially saturated solution. As used herein, "substantially saturated solution" means that the concentration of dissolved therapeutic agent in a solvent, such as water or another physiologically acceptable carrier, is at least about 75%, preferably  
20 at least about 80%, 85%, 90%, 95% or 100% of the limit of solubility of the therapeutic agent in the solvent. Alternatively, the concentration of the therapeutic agent is limited by the concentration that results in an undesirable toxic response from a patient. The  
25 substantially saturated solution is "associated with" the medical device in that the therapeutic agent is held in a cavity(ies) of the device, such as in an infusion style catheter such as a channel balloon catheter; or the therapeutic agent is coated onto the  
30 surface of the device as a coating per se or as part of a coating; or the substantially saturated solution is held within or passes through the medical device, such as in a needle injection catheter.

The present invention is described herein  
35 with specific reference to an expandable catheter as the medical device. Other medical devices within the

scope of the present invention include implantable devices such as needle injection catheters, hypodermic needles, stents, blood clot filters, vascular grafts, stent grafts, aneurysm filling coils, trans myocardial  
5 revascularization ("TMR") devices, percutaneous myocardial revascularization ("PMR") devices etc., as are known in the art.

The catheter used with the present invention is any suitable catheter such as, for example, an  
10 infusion catheter (such as a channeled balloon catheter as described in U.S. Patent No. 5,254,089, incorporated herein by reference, transport catheter, or microporous balloon catheter), an angioplasty balloon catheter, a double balloon catheter, or an infusing sleeve  
15 catheter, as are known in the art. The therapeutic agent is applied to, or is incorporated into, the expandable portion of such catheters. For example, the therapeutic agent is included as part of a polymer coating that is applied to said expandable portions.  
20 Alternatively, the therapeutic agent is incorporated directly into the expandable portion. Alternatively, the therapeutic agent is introduced into the catheter after the catheter is positioned to the target tissue by infusing the therapeutic agent through the infusion  
25 port of an infusion catheter.

In accordance with the present invention, once the catheter is positioned at the target location, the therapeutic agent is released at a pressure of not more than about 5 atmospheres, preferably not more than  
30 about 1 atmosphere, and more preferably, not more than about 0.1 atmosphere. The catheter is held at the target site for therapeutic agent delivery for a duration of not more than about 5 minutes, preferably not more than about 2 minutes, and more preferably not  
35 more than about 1 minute. Because the present invention makes use of concentration-driven molecular



diffusion rather than pressure-driven convention for the delivery of therapeutic agents, it allows for low delivery pressures and durations not heretofore known in the art. The delivery techniques of the present invention thus minimize the risk of tissue damage, ischemia, etc., commonly associated with conventional localized delivery techniques.

With specific reference to Fig. 1, the delivery of a therapeutic agent to a target location is accomplished with the use of a medical device 100 comprising a catheter 110 having an expandable portion 120. The expandable portion 120 of the catheter 110 is optionally coated with a polymer for holding the therapeutic agent during delivery into the body. The polymer coating 130 is preferably capable of absorbing a substantial amount of drug solution. The polymer coating 130 is placed onto the expandable portion 120 by any suitable mean such as, for example, by immersion, spraying, or deposition by plasma or vapor deposition. The polymer is typically applied to a thickness of about 1 to 30 microns, preferably about 2 to 5 microns. Very thin polymer coatings, e.g., of about 0.2-0.3 microns and much thicker coatings, e.g., more than 30 microns, are also possible. It is also within the scope of the present invention to apply multiple layers of polymer coating onto the expandable portion 120 of catheter 110. Such multiple layers can be of the same or different polymer materials, and may perform different functions (e.g., for biocompatibility, to control drug release, etc.).

The polymer coating 130 comprises any polymeric material capable of absorbing or otherwise holding the therapeutic agent to be delivered. The polymeric material is, for example, hydrophilic, hydrophobic, and/or biodegradable, and is preferably

selected from the group consisting of polycarboxylic acids, cellulosic polymers, gelatin, polyvinylpyrrolidone, maleic anhydride polymers, polyamides, polyvinyl alcohols, polyethylene oxides, glycosaminoglycans, polysaccharides, polyesters, polyurethanes, silicones, polyorthoesters, polyanhydrides, polycarbonates, polypropylenes, polylactic acids, polyglycolic acids, polycaprolactones, polyhydroxybutyrate valerates, polyacrylamides, polyethers, and mixtures and copolymers thereof. Coatings from polymer dispersions such as polyurethane dispersions (BAYHDROL, etc.) and acrylic latex dispersions are also within the scope of the present invention. Preferred polymers include polyacrylic acid as described in U.S. Pat. No. 5,091,205, the disclosure of which is incorporated herein by reference; and aqueous coating compositions comprising an aqueous dispersion or emulsion of a polymer having organic acid functional groups and a polyfunctional crosslinking agent having functional groups capable of reacting with organic acid groups, as described in U.S. Pat. No. 5,702,754, the disclosure of which is incorporated herein by reference.

The therapeutic agent is introduced onto the expandable portion 120, or alternatively, into the polymer coating 130, by any suitable method. For example, the therapeutic agent is placed in solution, which is thereafter applied to the expandable portion 120 or polymer coating 130 by any suitable means, including dipping into the drug solution or applying the solution by pipet or spraying. In the former method, the amount of drug loading is controlled by regulating the time the polymer coating 130 is immersed in the drug solution, the extent of polymer coating cross-linking, the interactions between the polymer and drug (i.e., bonding, Van der Waals forces, charge

interactions, etc.), the concentration of the drug in the solution and/or the amount of polymer coating 130. In another embodiment of the invention, the drug is incorporated directly into the polymer used in the polymer coating 130 prior to the application of the polymer as a coating onto a medical device. When the medical device used in the present invention is an infusion catheter 400, such as that shown in cross-section in Fig. 2, the substantially saturated solution of therapeutic agent (shown in Fig. 2 as 405) is not coated onto the catheter, but rather is delivered to the target tissue by infusing through the channels 410 of the infusion catheter 400.

The therapeutic agents used in the present invention include, for example, pharmaceutically active compounds, proteins, oligonucleotides, ribozymes, anti-sense genes, DNA compacting agents, gene/vector systems (i.e., anything that allows for the uptake and expression of nucleic acids), nucleic acids (including, for example, recombinant nucleic acids; naked DNA, cDNA, RNA; genomic DNA, cDNA or RNA in a non-infectious vector or in a viral vector which may have attached peptide targeting sequences; antisense nucleic acid (RNA or DNA); and DNA chimeras which include gene sequences and encoding for ferry proteins such as membrane translocating sequences ("MTS") and herpes simplex virus-1 ("VP22")), and viral, liposomes and cationic polymers that are selected from a number of types depending on the desired application. For example, biologically active solutes include anti-thrombogenic agents such as heparin, heparin derivatives, urokinase, PPACK (dextrophenylalanine proline arginine chloromethylketone), rapamycin, probucol, and verapamil; angiogenic and anti-angiogenic agents; anti-proliferative agents such as enoxaprin,

angiopeptin, or monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid; anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine; antineoplastic/antiproliferative/anti-mitotic agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitors; anesthetic agents such as lidocaine, bupivacaine, and ropivacaine; anti-coagulants such as D-Phe-Pro-Arg chloromethyl keton, an RGD peptide-containing compound, heparin, antithrombin compounds, platelet receptor antagonists, anti-thrombin anticodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet factors; vascular cell growth promoters such as growth factors, growth factor receptor antagonists, transcriptional activators, and translational promoters; vascular cell growth inhibitors such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin; cholesterol-lowering agents; vasodilating agents; agents which interfere with endogeneous vascoactive mechanisms; survival genes which protect against cell death, such as anti-apoptotic Bcl-2 family factors and Akt kinase; and combinations thereof. These and other compounds are added to the polymer coating using similar methods and routinely tested as set forth in the specification. Any modifications are routinely made by one skilled in the art.

Polynucleotide sequences useful in practice

of the invention include DNA or RNA sequences having a therapeutic effect after being taken up by a cell. Examples of therapeutic polynucleotides include anti-sense DNA and RNA; DNA coding for an anti-sense RNA; or  
5 DNA coding for tRNA or rRNA to replace defective or deficient endogenous molecules. The polynucleotides of the invention can also code for therapeutic polypeptides. A polypeptide is understood to be any translation product of a polynucleotide regardless of  
10 size, and whether glycosylated or not. Therapeutic polypeptides include as a primary example, those polypeptides that can compensate for defective or deficient species in an animal, or those that act through toxic effects to limit or remove harmful cells  
15 from the body. In addition, the polypeptides or proteins that can be incorporated into the polymer coating 130, or whose DNA can be incorporated, include without limitation, angiogenic factors including acidic and basic fibroblast growth factors, vascular  
20 endothelial growth factor, epidermal growth factor, transforming growth factor  $\alpha$  and  $\beta$ , platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor  $\alpha$ , hepatocyte growth factor and insulin like growth factor; growth factors;  
25 cell cycle inhibitors including CDK inhibitors; thymidine kinase ("TK") and other agents useful for interfering with cell proliferation, including agents for treating malignancies; and combinations thereof. Still other useful factors, which can be provided as  
30 polypeptides or as DNA encoding these polypeptides, include monocyte chemoattractant protein ("MCP-1"), and the family of bone morphogenic proteins ("BMP's"). The known proteins include BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11,  
35 BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16. Currently preferred BMP's are any of BMP-2, BMP-3, BMP-4, BMP-5,

BMP-6 and BMP-7. These dimeric proteins can be provided as homodimers, heterodimers, or combinations thereof, alone or together with other molecules. Alternatively or, in addition, molecules capable of inducing an upstream or downstream effect of a BMP can be provided. Such molecules include any of the "hedgehog" proteins, or the DNA's encoding them.

In one exemplary embodiment of the present invention, the medical device has recombinant nucleic acid incorporated therein, wherein the recombinant nucleic acid comprises a viral vector having linked thereto an exogenous nucleic acid sequence. "Exogenous nucleic acid sequence" is used herein to mean a sequence of nucleic acids that is exogenous to the virus from which the vector is derived. The concentration of the viral vector, preferably an adenoviral vector, is at least about  $10^{10}$  plaque forming units ("p.f.u.") per milliliter ("ml"), preferably at least about  $10^{11}$  p.f.u. per ml. Alternatively, the concentration of the viral vector is limited by the concentration that results in an undesirable immune response from a patient.

After the therapeutic agent is incorporated into the inflatable portion 120 or coating 130, the medical device 100 is introduced into the body and positioned to a target location through a body cavity or vasculature (e.g., coronary arteries, portal vein, ileofemoral vein, etc.) by torquing or other known techniques. Once the medical device 100 is positioned to a target location within the body, the expandable portion 120 is optionally expanded and the drug is released at a pressure of not more than about 5 atmospheres, preferably not more than about 1 atmosphere, and more preferably, not more than about 0.1 atmosphere. The medical device 100 is held at the

target location for a duration of not more than about 5 minutes, preferably not more than about 2 minutes, and more preferably not more than about 1 minute. After delivery, the medical device 100 is removed from the  
5 body by known techniques.

In one embodiment, the medical device 100 of the present invention includes a stent 300 (Fig. 3) for placement in a body lumen. The present invention can thus be used for the dual purpose of localized drug  
10 delivery and stent placement. As known in the art, stents are tubular support structures that are implanted inside tubular organs, blood vessels or other tubular body lumens. The stent used with the present invention is of any suitable design, and is either  
15 self-expanding or balloon-expandable. The stent is made of any suitable metallic (e.g., stainless steel, nitinol, tantalum, etc.), polymeric (e.g., polyethylene terephthalate, polyacetal, polylactic acid, polyethylene oxide - polybutylene terephthalate  
20 copolymer, etc.) or biodegradable material. The stent 300 is preferably metallic and configured in a mesh design, as shown in Fig. 3. When used with the present invention, the stent 300 is placed over the expandable portion 120 of the catheter 110. The medical device  
25 100 is thereafter delivered to a target location within the body. In this embodiment, the target location is situated within a body lumen. When the expandable portion 120 is expanded during the release of the drug agent from within the expandable portion 120 or the  
30 polymer coating 130, the stent 300 is likewise expanded. After the drug agent has been released from the expandable portion 120 or the polymer coating 130, the expandable portion 120 is compressed or deflated. The stent 300, however, remains in its expanded state  
35 within the body lumen.

Referring to the embodiment of the invention illustrated in Fig. 4, the expandable portion 120 of the catheter 110 is optionally covered by a protective sheath 210 while the medical device 100 is inserted  
5 into the body and positioned at a target location within a body lumen 200. Such a sheath is particularly advantageous in the case of long arterial transit times (i.e., to position the catheter to the target location) or when the therapeutic agent to be delivered is highly  
10 toxic. As the expandable portion 120 is positioned at a target occluded site 220, the protective sheath 210 is drawn back to expose the expandable portion 120 and thus to allow diffusion of the therapeutic agent into the target location 220. Alternatively, the sheath 210  
15 remains stationary while the catheter 110 moves the expandable portion 120 forward into the occluded region. The sheath 210 protects the agent and coating 130, thus inhibiting premature release of the therapeutic agent.

20 In one embodiment, the medical device is a needle injection catheter rather than a balloon catheter. In this embodiment, the therapeutic agent is delivered to tissues atraumatically over a relatively short and clinically relevant time period, typically on  
25 the order of several seconds, by injecting a small volume (e.g., about 0.001 to about 1 ml) of a substantially saturated solution of therapeutic agent. Because the solution is substantially saturated, the concentration gradient of therapeutic agent resulting  
30 from injection drives the therapeutic agent deep into tissue by diffusion. Thus, in contrast to conventional local drug delivery techniques that make use of infusion pressure and volume to drive the drug deep into tissue, the method of the present invention  
35 achieves deep tissue penetration by a concentration



driven mechanism. Consequently, the method of the present invention allows for the injection of therapeutic agent into tissues at low pressures, such as 1 atm or less, and with small volumes. One  
5 advantage of this embodiment over conventional techniques is that the low infusion pressure minimizes tissue damage, thus resulting in a potential increase in efficacy, transfection efficiency or the like.

Useful therapeutic applications to which the present invention can be applied include, without  
10 limitation, methods for treating, ameliorating, reducing and/or inhibiting any lumen or tissue injury, including those that result in denuding the interior wall of a lumen, namely its endothelial lining,  
15 including the lining of a blood vessel, urethra, lung, colon, urethra, biliary tree, esophagus, prostate, fallopian tubes, uterus, vascular graft, or the like. Such injuries result from disease, as in the case of atherosclerosis or urethral hyperplasia (strictures),  
20 and/or from mechanical injury from, for example, deployment of an endolumenal stent or a catheter-based device, including balloon angioplasty and related devices.

Vascular therapies that benefit using the methods disclosed herein include, without limitation,  
25 cardiomyopathies, cardiac and cerebral strokes, embolisms, aneurysms, atherosclerosis, and peripheral and cardiac ischemias. Delivery of genes encoding proteins competent to induce collateral blood vessel  
30 formation can be used to advantage in treating these disorders. Delivery of genes encoding proteins competent to interfere with neointimal (smooth muscle) cell proliferation also is particularly useful in treating restenosis.

35 Non-vascular therapies that benefit using the methods disclosed herein include urogenital

applications, including therapies for incontinence, kidney stones and the like. Here devices typically are implanted for a prescribed period of time and local delivery of genetic or chemical agents competent to induce an antibacterial, anti-inflammatory, or anti-encrustation effect are advantageous. In other applications, the delivery of anti-inflammatory agents, genetic or otherwise, is used to treat prostatitis, interstitial cystitis and other urogenital inflammatory disorders. Antiproliferative agents, genetic or otherwise, also can be used in endometriosis therapies. Still another application is in the delivery of anticancer agents, genetic or otherwise. The methods of the invention can be applied to therapies for bladder, prostate and uterine cancer. Similarly, delivery of agents to the interior of the lung to treat lung disorders, including cancers, cystic fibrosis and the like can be used to advantage.

The methods of the present invention can also be used to deliver diagnostic and/or imaging agents, including ultrasound contrasting agents such as perfluorocarbon. Other contrasting agents are well known to those skilled in the art. The contrasting agent is typically a microbubble encapsulated in a lipid, lipid-like or protein coat for catheter-based delivery. The microbubble further can have a tissue-targeting agent on its surface. Once delivered to the site of interest, the microbubble is burst or otherwise detected using ultrasound enhancement. The contrasting agent also can be combined with a therapeutic agent, genetic or otherwise, which then is delivered when the bubble is burst by ultrasound enhancement. Delivery to large surface areas such as lung and uterus interiors can benefit from this protocol.

Penetration enhancers are optionally used in any embodiment of the present invention. As is known

in the art, penetration enhancers are substances or processes which facilitate the transport of solutes across biological membranes. When used in accordance with the present invention, penetration enhancers

5 further increase the rate of penetration of therapeutic agents into tissues, thus allowing for more efficient drug transfer. Common classes of penetration enhancers include chelating agents such as EDTA, citric acid, salicylates, derivatives of collagen and diketones;

10 surfactants such as SDS and polyoxyethylene-9-lauryl ether; non-surfactants such as cyclic ureas, 1-alkyl and 1-alkenylazacycloalkanone derivatives; bile salts and derivatives such as sodium deoxycholate, sodium, taurocholate, STDHF, and sodium glycodihydrofusidate; fatty

15 acids and derivatives such as oleic acid, caprylic acid, capric acid, acylcarnitines, acylcholines, and mono and diglycerides; divalent and polyvalent cations; and enzymes such as elastase. Alternatively, a penetration enhancer used in conjunction with the

20 present invention includes a process such as ultrasound, the application of an electric field, and/or other processes which increase the rate of penetration of therapeutic agents into tissues.

The invention is further described with

25 reference to the following non-limiting examples.

#### Examples

All examples described herein were conducted for the in vivo delivery of an adenoviral trans-gene.

30 The trans-gene used was recombinant nuclear specific  $\beta$ -galactosidase under the control of the cytomegalovirus promoter. Viral titer was measured by standard plaque assay using 293 cells. Viral solutions were thawed on ice and diluted with saline to appropriate

35 concentrations. The viral solutions were used immediately after dilution.

New Zealand white rabbits (3.5-4.0 kg) were anesthetized with ketamine (10 mg/kg) and acepromazine (0.2 mg/kg) following prededication with xylazine (2 mg/kg). The bilateral external iliac arteries were used for all experiments. A 5 French ("Fr.") introducer sheath was positioned in the right common carotid artery under surgical exposure. An angioplasty catheter was introduced via the introducer sheath to the lower abdominal aorta under fluoroscopic guidance. Angiography of the iliac arteries was performed using 2 ml of non-ionic contrast media. Rabbit weights were monitored and kept within 3.5 to 4.0 kg to insure a balloon to artery ratio of about 1.2:1. Arteries were denuded of endothelium by conducting a triple inflation injury prior to delivery. Injury was conducted using a 2.0 cm, 3.0 mm diameter balloon catheter introduced with a 0.014 inch guidewire via the right common carotid artery into either the right or left external iliac artery. The catheter was inflated to pressure with 50% dilution of contrast media at 6 atm, three times for one minute per inflation. After treatment of one iliac artery, the contralateral iliac artery was treated with a new balloon catheter.

Replication-deficient adenoviral vector gene delivery was accomplished in vivo with the use of both infusion style local delivery catheters and hydrogel coated angioplasty catheters. The infusion based devices were used to deliver viral particles to the vessel wall by pressure driven convection combined with concentration driven diffusion. Transmural hydraulic pressure was created at the vessel wall and modulated using these devices by infusion the viral solution under a known applied pressure. Two infusion devices were used to modulate pressure at a constant delivery time: the Channeled balloon catheter (Boston Scientific Corporation, Natick, MA) was used for low to

moderate infusion pressures and the Transport catheter (Boston Scientific Corporation, Natick, MA) was used for high pressure infusions. Concentration was modulated at a constant infusion pressure of approximately 0.1 atm. Additionally, hydrogel coated angioplasty balloons were used to deliver virus to the vessel wall by a purely concentration driven diffusive mechanism. The hydrogel coated angioplasty balloons were coated with a crosslinked polyacrylic acid polymer.

Example 1 - Delivery with a Channeled Balloon Catheter

Replication deficient adenoviral vector gene delivery was accomplished in vivo with the use of a channeled balloon catheter 2.0 cm in length and 3.0 mm in diameter. The catheter was introduced with a 0.014 inch guidewire via the right common carotid artery into either the right or left external iliac artery. The balloon was inflated to a nominal pressure of about 6 atm, whereupon gene delivery was accomplished at an infusion pressure of about 0.1 or 3 atm. Either of 3 ml, 500 microliters (" $\mu$ l"), or 200  $\mu$ l of viral solution was infused through the infusion port of the catheter using a 1 ml or 5 ml syringe. Infusions of 3 ml were necessary to create higher infusion pressures. The solution was infused slowly over approximately 2 minutes while monitoring infusion pressure using an online pressure transducer. Balloons were deflated and removed after either 2 or 30 minutes had elapsed from the time of positioning the catheter at the target site.

Example 2 - Delivery with a Transport Catheter

Viral solutions were infused locally at high pressure using the Transport catheter 2.0 cm in length and 3.0 mm in diameter. The catheter was introduced

with a 0.014 inch guidewire via the right common carotid artery into either the right or left external iliac artery. The balloon was inflated to a nominal pressure of about 6 atm, whereupon gene delivery was accomplished at an infusion pressure of about 8 atm. Approximately 3 ml of viral solution was infused through the infusion port of the catheter using a 5 ml syringe. The solution was infused slowly over approximately 2 minutes while monitoring infusion pressure using an online pressure transducer. Balloons were deflated and removed after about 2 minutes.

Example 3 - Delivery with a Hydrogel Coated Balloon Catheter

Virus was applied to the hydrogel coating of angioplasty balloons by slowly applying 25  $\mu$ l of a  $1.7 \times 10^{11}$  pfu/ml adenoviral  $\beta$ -galactosidase stock solution (replication deficient adenovirus carrying the E coli  $\beta$ -galactosidase gene) onto the coating using a micro-pipette. A 2.0 cm long, 3.0 mm diameter loaded hydrogel coated balloon catheter was placed within a protective sheath and inflated to 2 atm. The entire assembly was advanced over a 0.014 inch guidewire via the right common carotid artery to the bifurcation leading to the external iliacs. The balloon was then deflated and quickly advanced further to either the right or left external iliac artery. Viral delivery was allowed to occur for either 2 or 30 min.

Comparison of Examples 1 to 3

Three days after transfection, iliac arteries were harvested immediately after perfusion with heparinized 0.9% saline solution via the lower abdominal aorta. The harvested vessels were washed with cold phosphate-buffered saline (PBS), fixed in 1% paraformaldehyde for 10 min, washed in PBS post-

fixation.  $\beta$ -galactosidase activity was assessed by incubating arteries in X-GAL chromogen overnight at 37°C. After staining, vessels were rinsed in PBS and post-fixed in 1% paraformaldehyde.

5           Vessels were opened longitudinally and photographed through a dissecting microscope for gross assessment. The dark blue staining sites were considered transfected regions. The target-zone, usually at or near the center of the delivery site, was  
10 cross-sectioned and subsequently processed for histologic analysis. Specimens were embedded in paraffin sectioned into 5  $\mu$ m sections and counter stained with hematoxylin and eosin. Slides were examined by light microscopy for expression of the LacZ  
15 transgene product, nuclear  $\beta$ -galactosidase, and were considered positive only when dark blue staining was observed. Transfection efficiency was determined by counting stained versus total medial nuclei in each arterial section.

20

#### Effect of Applied Pressure on Transfection

As shown in Table I, applied pressures of 3 and 8 atm did not significantly affect viral delivery from infusion-based devices. Transfection efficiency  
25 of a 3 ml viral solution was  $2.30 \pm 0.64\%$  when infused at approximately 3 atm and  $1.05 \pm 0.21\%$  when infused at an average pressure of 8 atm using Channeled and Transport catheters, respectively.

30

35

Table I. Influence of infusion volume and pressure on viral transfection efficiency.

Device	infused conc. (pfu/ml)	viral dose (pfu)	infusion volume (ml)	infusion pressure (atm)	% transduc- tion
hydrogel	N/A	$4.3 \times 10^9$	N/A	N/A	$2.04 \pm 0.75$
channel	$1.7 \times 10^9$	$5.1 \times 10^9$	3	3	$2.30 \pm 0.64$
transport	$1.7 \times 10^9$	$5.1 \times 10^9$	3	8	$1.05 \pm 0.21$

p=NS for all combinations

A comparable level of gene transfection,  $2.04 \pm 0.75\%$ , was achieved at zero hydraulic pressure (no infusion volume) when the virus was delivered passively from a hydrogel coated balloon, providing an indication that molecular diffusion rather than convection is the predominant mechanism for viral transport in the vessel wall. Viral infusion volume and pressure were determined not to have a statistically significant effect (p = not significant ("NS")) on transfection efficiency under each condition tested in Table I (all data were compared by a one-way analysis of variants).

#### Effect of Infusion Volume on Cellularity

Cellularity was assessed in 5 micron histological cross-sections by counting the number of nuclei stained by hematoxylin and eosin. Cellularity is expressed as the number of nuclei per cross-section. The higher volume deliveries, and consequently higher pressure infusions, from Channeled and Transport balloon catheters resulted in a significant loss of cellularity in the treated segment, as shown in Table II.



Table II. Influence of delivery parameters on cellularity.

Device	infusion volume (ml)	infusion pressure (atm)	cellularity
none <sup>1</sup>	0	0	845±34
hydrogel <sup>2</sup>	N/A	N/A	833±17
channel <sup>3</sup>	0.2	0.1	800±22
channel <sup>4</sup>	0.5	0.1	863±24
channel <sup>5</sup>	3	3	592±38
transport <sup>6</sup>	3	8	600±34

p < 0.05 for 1, 2, 3, 4 versus 5, 6

Sections from these arteries demonstrated a reduction in medial smooth muscle cell number as indicated by a loss of visible cell nuclei for vessels treated with 3 ml of viral solution. In contrast, infusion volumes of 500  $\mu$ l and less did not exhibit any observable detrimental effects on vessel wall cellularity.

#### Effect of Concentration on Transfection

The effect of an applied concentration on in vivo gene delivery was examined by delivering 500  $\mu$ l of viral solution at three concentrations,  $1.7 \times 10^{10}$ ,  $5.6 \times 10^{10}$ , and  $1.7 \times 10^{11}$  pfu/ml, under an infusion pressure of 0.1 atm. Transfection increased by an order of magnitude from  $1.8 \pm 0.4\%$  to  $17.8 \pm 3.2\%$ , in direct proportion to the increase in viral concentration from  $1.7 \times 10^{10}$  to  $1.7 \times 10^{11}$  pfu/ml. Such transfection levels are considered high for in-vivo  $\beta$ -galactosidase because of the presence of endogenous inhibitors. Histological staining of these arteries demonstrated a greater number of stained blue cells deeper into the media at the higher concentration of delivered virus relative to the lower concentration. Previous studies (Schulick et

al., "In vivo Gene Transfer into Injured Carotid Arteries. Optimization and Evaluation of Acute Toxicity," 91 Circulation 2407-14 (1995)) have demonstrated a toxic response in the vessel wall when  
5  $1 \times 10^{11}$  pfu/ml of adenoviral  $\beta$ -galactosidase was delivered to rat carotid arteries. Here, the inventors have surprisingly shown that the channeled balloon catheter can be used to deliver viral solutions to  
10 rabbit iliac arteries at viral concentrations as high as  $1.7 \times 10^{11}$  pfu/ml without an adverse effect on cellularity and with no observable inflammatory response.

#### Effect of Delivery Time on Transfection

15 The effect of delivery time on gene transfection was examined using hydrogel coated balloons. The balloons were left in contact with the vessel wall for either 2 or 30 minutes. As shown in Table III, transfection efficiency was  $1.57 \pm 0.05\%$  and  
20  $2.04 \pm 75\%$  for delivery at 30 minutes and 2 minutes, respectively. In a related set of experiments,  $200 \mu\text{l}$  of viral solution infused through a channeled balloon catheter over 2 minutes followed by no incubation or a  
25 30 minute incubation where the balloon was left inflated. Transfection was  $2.53 \pm 0.44$  and  $2.00 \pm 0.52$  for delivery with or without a 30 minute incubation, respectively.

30

35

40

Table III. Influence of delivery and incubation time on viral transfection efficiency.

Device	infused conc. (pfu/ml)	viral dose (pfu)	delivery time (min)	incubat. time (min)	% transduction
hydrogel <sup>1</sup>	N/A	4.3x10 <sup>9</sup>	2	0	2.04±0.75
hydrogel <sup>2</sup>	N/A	4.3x10 <sup>9</sup>	30	0	1.57±0.05
channel <sup>3</sup>	26x10 <sup>9</sup>	5.1x10 <sup>9</sup>	2	0	2.52±0.44
channel <sup>4</sup>	26x10 <sup>9</sup>	5.1x10 <sup>9</sup>	2	30	2.00±0.52

p=NS for 1 vs. 2 and 3 vs. 4

Example 4

In accordance with an embodiment of the present invention, heparin is locally delivered with the use of an infusion style balloon, such as in a channeled balloon catheter. A substantially saturated solution of heparin, having a concentration of about 1 gram per 20 ml of water, is infused at a target location for about 2 minutes at a pressure of about 0.1 atm. Using this approach, relatively small volumes of approximately 1 ml may be infused to achieve a therapeutic result, in comparison to the relatively higher volumes and pressures used in conventional techniques.

Example 5

In accordance with an embodiment of the present invention, verapamil is locally delivered with the use of an infusion style balloon, such as in a channeled balloon catheter. A substantially saturated solution of verapamil hydrochloride, having a concentration of about 62 mg/ml (i.e., about 75% of the solubility limit of 82 mg/ml for verapamil hydrochloride in water), is infused at a target location for about 2 minutes at a pressure of about 0.1

atm. Using this approach, relatively small volumes of approximately 1 ml may be infused to achieve a therapeutic result, in comparison to the relatively higher volumes and pressures used in conventional techniques.

#### Summary of Examples 1-5

By way of the present invention, a 2-minute clinically relevant delivery time was shown to be effective in achieving high levels of gene transfection in vivo. While prior studies have used delivery times greater than 20 minutes or an additional 30 minute incubation period post delivery from an infusion device such as a channel balloon catheter, the present inventors have shown that a 2 minute delivery time is at least as effective as 30 minute delivery times. Since molecular diffusion is time-dependent, longer delivery times may have a positive effect under different conditions such as higher viral doses. In addition, a 30 minute incubation period post viral delivery from an infusion device, i.e. channel balloon catheter, was shown not to have a significant effect on gene expression. Thus, once the artery is reperfused and the concentration gradient is reversed, the virus does not back diffuse into the lumen. As the inventors have shown, long delivery times and extended incubation periods are not necessary for effective gene transfer once conditions have been optimized for a particular delivery device.

#### Example 6 - Delivery with a Needle Injection Catheter

Recombinant replication deficient adenoviral particles encoding the gene for  $\beta$  galactosidase were injected into porcine myocardia using a needle injection catheter. A volume of 100  $\mu$ l of viral solution was injected at a concentration of  $1 \times 10^9$  pfu/ml

and the results compared to those obtained using a 100  $\mu$ l dose injection at  $1 \times 10^{10}$  pfu/ml. Greater penetration of the virus was observed with the higher concentration injection, thus demonstrating greater diffusion of the virus due to the corresponding higher concentration gradient. Moreover, the higher concentration injection demonstrated greater transfection when compared to 250  $\mu$ l injections at lower concentrations of  $1 \times 10^9$  pfu/ml, thus demonstrating that high volumes are not necessary to achieve high degrees of transfection.

The inventors have demonstrated that viral particles penetrate arterial tissue in a manner analogous with a molecular diffusion mechanism. Consistent with this finding, the inventors have determined that concentration of therapeutic agent is the critical parameter for transport, and thus gene expression or therapeutic effect, in a vessel wall. The present invention is used to achieve significant transfection levels or therapeutic agent levels at a local site by delivering a small volume of concentrated therapeutic agent solution through a local delivery catheter at low pressure. Conversely, the inventors have determined that variations in applied pressure, which drives convective transport, does not significantly affect gene expression or drug delivery and/or uptake. Moreover, the inventors have found that gene expression occurs when a viral solution is delivered in a clinically relevant time frame of 2 minutes, thus indicating that longer times are not necessary to achieve efficient gene transfer.

What is claimed is:

- 1     1.   A method of site-specifically delivering a  
2           therapeutic agent to a target location within a  
3           body cavity, vasculature, or tissue of a mammal,  
4           comprising the steps of:  
5                providing a medical device having a  
6                substantially saturated solution of therapeutic  
7                agent associated therewith;  
8                introducing said medical device into the body  
9                cavity, vasculature, or tissue;  
10               releasing a volume of said solution of  
11               therapeutic agent from said medical device at the  
12               target location at a pressure of from about 0 to  
13               about 5 atmospheres for a time period of up to  
14               about 5 minutes; and  
15               withdrawing said medical device from said  
16               body cavity, vasculature, or tissue.
- 1     2.   The method of claim 1, wherein said substantially  
2           saturated solution comprises said therapeutic  
3           agent in a physiologically acceptable carrier, and  
4           the concentration of said therapeutic agent is  
5           within the range of about 80% to about 100% of the  
6           solubility limit of said therapeutic agent in said  
7           carrier.
- 1     3.   The method of claim 1, wherein said pressure is  
2           not more than about 1 atmosphere.
- 1     4.   The method of claim 1, wherein said pressure is  
2           not more than about 0.1 atmospheres.
- 1     5.   The method of claim 1, wherein said step of  
2           releasing occurs for a time period of up to about  
3           2 minutes.

- 1       6.    The method of claim 1, wherein said volume of said  
2            solution of therapeutic agent is about 0.001 ml to  
3            about 1 ml.
- 1       7.    The method of claim 1, wherein said therapeutic  
2            agent is selected from the group consisting of  
3            pharmaceutically active compounds, proteins,  
4            oligonucleotides, DNA compacting agents,  
5            recombinant nucleic acids, gene/vector systems,  
6            and nucleic acids.
- 1       8.    The method of claim 7, wherein  
2            said therapeutic agent is a recombinant  
3            nucleic acid comprising a viral vector having  
4            linked thereto an exogenous nucleic acid sequence;  
5            and  
6            the concentration of said viral vector is at  
7            least about  $10^{10}$  p.f.u. per ml.
- 1       9.    The method of claim 1, wherein said medical device  
2            is a catheter.
- 1       10.   The method of claim 9, wherein said catheter is a  
2            channeled balloon catheter.
- 1       11.   The method of claim 9, wherein said catheter is a  
2            transport catheter.
- 1       12.   The method of claim 9, wherein said catheter is an  
2            infusion sleeve catheter.
- 1       13.   The method of claim 9, wherein said catheter is a  
2            balloon catheter having an expandable portion.
- 1       14.   The method of claim 1, wherein said medical device  
2            comprises a needle.

- 1      15. The method of claim 14, wherein said medical  
2                      device is a needle injection catheter.
- 1      16. The method of claim 14, wherein said medical  
2                      device is a hypodermic needle.
- 1      17. The method of claim 1, wherein said medical device  
2                      is an implantable medical device.
- 1      18. The method of claim 17, wherein said medical  
2                      device is a stent.
- 1      19. The method of claim 17, wherein said medical  
2                      device is a blood clot filter.
- 1      20. The method of claim 17, wherein said medical  
2                      device is a vascular graft.
- 1      21. The method of claim 13, further comprising the  
2                      steps of:  
3                      coating said expandable portion with a  
4                      polymer coating; and  
5                      incorporating said therapeutic agent into  
6                      said polymer coating.
- 1      22. The method of claim 21, wherein said coating  
2                      comprises a polymer selected from the group  
3                      consisting of polycarboxylic acids, cellulosic  
4                      polymers, gelatin, polyvinylpyrrolidone, maleic  
5                      anhydride polymers, polyamides, polyvinyl  
6                      alcohols, polyethylene oxides, glycosaminoglycans,  
7                      polysaccharides, polyesters, polyurethanes,  
8                      silicones, polyorthoesters, polyanhydrides,  
9                      polycarbonates, polypropylenes, polylactic acids,  
10                     polyglycolic acids, polycaprolactones,



- 11 polyhydroxybutyrate valerates, polyacrylamides,  
12 polyethers, polyurethane dispersions, acrylic  
13 latex dispersions, polyacrylic acid, and mixtures  
14 and copolymers thereof.
- 1 23. The method of claim 13, further comprising the  
2 steps of:  
3 placing a sheath over said expandable portion  
4 before said step of positioning said medical  
5 device to said target location; and  
6 removing said expandable portion from said  
7 sheath before said step of releasing said solution  
8 of therapeutic agent from said medical device.
- 1 24. The method of claim 1, wherein said target  
2 location is within a blood vessel.
- 1 25. The method of claim 1, wherein said target  
2 location is within the gastrointestinal tract.
- 1 26. The method of claim 1, wherein said target  
2 location is within the heart.
- 1 27. The method of claim 1, wherein said target  
2 location is within the urological system.
- 1 28. The method of claim 1, wherein said target  
2 location is within the gynecological system.
- 1 29. The method of claim 1, wherein said solution is  
2 applied to said medical device as a coating.
- 1 30. A system for localized delivery of a therapeutic  
2 agent to a target location within a body cavity,  
3 vasculature, or tissue of a mammal, comprising a  
4 medical device that delivers the therapeutic agent

- 5 at a pressure of from about 0 to about 5  
6 atmospheres, said medical device having a  
7 substantially saturated solution of said  
8 therapeutic agent associated therewith.
- 1 31. The system of claim 30, wherein said therapeutic  
2 agent is selected from the group consisting of  
3 pharmaceutically active compounds, proteins,  
4 oligonucleotides, DNA compacting agents,  
5 recombinant nucleic acids, gene/vector systems,  
6 and nucleic acids.
- 1 32. The system of claim 31, wherein  
2 said therapeutic agent is a recombinant  
3 nucleic acid comprising a viral vector having  
4 linked thereto an exogenous nucleic acid sequence;  
5 and  
6 the concentration of said viral vector is at  
7 least about  $10^{10}$  p.f.u. per ml.
- 1 33. The system of claim 30, wherein said medical  
2 device is a catheter.
- 1 34. The system of claim 33, wherein:  
2 said catheter includes an expandable portion;  
3 and  
4 said expandable portion is coated with a  
5 polymer coating that includes said substantially  
6 saturated solution.
- 1 35. The system of claim 34, wherein said coating  
2 comprises a polymer selected from the group  
3 consisting of polycarboxylic acids, cellulosic  
4 polymers, gelatin, polyvinylpyrrolidone, maleic  
5 anhydride polymers, polyamides, polyvinyl  
6 alcohols, polyethylene oxides, glycosaminoglycans,

7 polysaccharides, polyesters, polyacrylamides,  
8 polyethers, polyurethane dispersions, acrylic  
9 latex dispersions, and mixtures and copolymers  
10 thereof.

1 36. The system of claim 33, further comprising a stent  
2 at least partially surrounding said catheter.

1 37. The system of claim 30, wherein said medical  
2 device comprises a needle.

1 38. The system of claim 37, wherein said medical  
2 device is a needle injection catheter.



1 39. The system of claim 37, wherein said medical  
2 device is a hypodermic needle.


1 40. The system of claim 30, wherein said medical  
2 device is an implantable medical device.

1 41. The system of claim 40, wherein said medical  
2 device is a stent.


1 42. The system of claim 40, wherein said medical  
2 device is a blood clot filter.

1 43. The system of claim 40, wherein said medical  
2 device is a vascular graft.

**Fig. 1****Fig. 2**



**Fig. 3**




**Fig. 4**

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61M 29/02</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 00/32267</b> <b>(43) International Publication Date:</b> 8 June 2000 (08.06.00)
<b>(21) International Application Number:</b> PCT/US99/28544 <b>(22) International Filing Date:</b> 3 December 1999 (03.12.99)  <b>(30) Priority Data:</b> 09/204,254 3 December 1998 (03.12.98) US  <b>(71) Applicants:</b> SCIMED LIFE SYSTEMS, INC. [US/US]; One Scimed Place, Maple Grove, MN 55311-1566 (US). ST. ELIZABETH'S MEDICAL CENTER, INC. [US/US]; 736 Cambridge Street, Boston, MA 02135 (US).  <b>(72) Inventors:</b> PALASIS, Maria; 65 Martin Road, Wellesley, MA 02181 (US). WALSH, Kenneth; 207 Judy Farm Road, Carlisle, MA 01741 (US).  <b>(74) Agents:</b> CAVANAUGH, David, L. et al.; Kenyon & Kenyon, Suite 700, 1500 K Street, N.W., Washington, DC 20005 (US).	<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>  <b>(88) Date of publication of the international search report:</b> 23 November 2000 (23.11.00)	

**(54) Title:** DEVICE FOR LOCALLY DELIVERING A DRUG IN A BODY CAVITY**(57) Abstract**

A method of site-specifically delivering a therapeutic agent to a target location within a body cavity. The method comprises the steps of providing a medical device such as a catheter stent filter or vascular graft with a coating containing that agent. Introducing the medical device into the body cavity releasing a volume of the solution of therapeutic agent from the medical device by diffusion contacting the target site surface. In another embodiment, the present invention includes a system for delivering a therapeutic agent into a body cavity comprising a medical device injecting the agent via the needle.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/28544

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61M29/02

According to International Patent Classification (IPC) or to both national classification and IPO

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61F A61M A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 11896 A (BOSTON SCIENTIFIC CORPORATION) 23 July 1992 (1992-07-23) abstract	30-36, 40,41 37-39, 42,43
Y	page 1, line 30 -page 4, line 30; figures 1C-E,2-6	
Y	US 5 599 294 A (LUNDQUIST ET AL.) 4 February 1997 (1997-02-04) abstract; figures 1,3,5	37-39
Y	US 5 800 525 A (GOLDSTEEN ET AL.) 1 September 1998 (1998-09-01) abstract column 3, line 41 - line 61; figures 1,7	42
	--- -/-- ---	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

10 July 2000

Date of mailing of the international search report

19. 07. 2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2  
NL - 2200 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Michels, N



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/28544

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 364 787 A (EXPANDABLE GRAFTS PARTNERSHIP) 25 April 1990 (1990-04-25) abstract; figures 5,6 ---	43
X	WO 97 41916 A (EMED CORPORATION) 13 November 1997 (1997-11-13) abstract; figures 1-5 ---	30-36, 40,41
X	US 5 464 395 A (FAXON ET AL.) 7 November 1995 (1995-11-07) abstract; figures 1,12,17,18 ---	30-39
A	US 5 102 402 A (TRESCONY ET AL.) 7 April 1992 (1992-04-07) ---	
A	GB 2 153 235 A (MEADOX MEDICALS, INC.) 21 August 1985 (1985-08-21) -----	

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 99/28544

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-29  
because they relate to subject matter not required to be searched by this Authority, namely:  
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☒ Claims Nos.: -  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☒ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

## Continuation of Box I.2

Present claims 30-32, 40 relate to an extremely large number of possible apparatus. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the apparatus claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to claims 33-36 and 41-43 (also referring to the definition of the first subject matter in the Non-Unity declaration).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

**FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210**

**This International Searching Authority found multiple (groups of) inventions in this international application, as follows:**

**1. Claims: 30-36,40-43**

**Device for delivering a drug locally in a body cavity releasing the drug out of a coating containing said drug.**

**2. Claims: 30, 37-39**

**Device for delivering a drug locally in a body cavity injecting the drug via a needle.**

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. national Application No

PCT/US 99/28544

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9211896 A	23-07-1992	US 5304121 A	19-04-1994
		CA 2098984 A	29-06-1992
		DE 69131486 D	02-09-1999
		DE 69131486 T	17-02-2000
		EP 0565604 A	20-10-1993
		EP 0920843 A	09-06-1999
		ES 2137179 T	16-12-1999
		JP 6503984 T	12-05-1994
		WO 9211895 A	23-07-1992
		US 5674192 A	07-10-1997
		US 5954706 A	21-09-1999
		US 5843089 A	01-12-1998
US 5599294 A	04-02-1997	AT 132046 T	15-01-1996
		AU 671405 B	22-08-1996
		AU 2047595 A	10-08-1995
		AU 657235 B	02-03-1995
		AU 4999893 A	15-03-1994
		BR 9306893 A	08-12-1998
		CA 2121032 A,C	03-03-1994
		CA 2226484 A	03-03-1994
		DE 4305663 A	17-02-1994
		DE 69301143 D	08-02-1996
		DE 69325164 D	08-07-1999
		DE 69325164 T	25-05-2000
		EP 0611314 A	24-08-1994
		EP 0629382 A	21-12-1994
		EP 0893101 A	27-01-1999
		ES 2084510 T	01-05-1996
		ES 2134295 T	01-10-1999
		FI 950584 A	04-04-1995
		FR 2694700 A	18-02-1994
		GB 2269538 A,B	16-02-1994
		IL 104647 A	31-12-1995
		JP 7503645 T	20-04-1995
		MX 9304905 A	29-04-1994
		NZ 255687 A	20-12-1996
		US 5370675 A	06-12-1994
		US 5385544 A	31-01-1995
		US 5421819 A	06-06-1995
		US 6022334 A	08-02-2000
		US 5435805 A	25-07-1995
		WO 9404220 A	03-03-1994
		US 5409453 A	25-04-1995
		US 5470308 A	28-11-1995
		US 5366490 A	22-11-1994
		US 5556377 A	17-09-1996
		US 5720718 A	24-02-1998
		US 5542915 A	06-08-1996
		US 5470309 A	28-11-1995
		US 5554110 A	10-09-1996
		US 5549644 A	27-08-1996
		US 5484400 A	16-01-1996
		US 5630794 A	20-05-1997
		US 5514131 A	07-05-1996
		US 5672153 A	30-09-1997
		US 5720719 A	24-02-1998
		US 5531676 A	02-07-1996

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/US 99/28544

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5599294 A		US 5536240 A US 5542916 A US 5540655 A US 5667488 A	16-07-1996 06-08-1996 30-07-1996 16-09-1997
US 5800525 A	01-09-1998	NONE	
EP 0364787 A	25-04-1990	AT 72955 T AU 623438 B AU 4248589 A BR 8905130 A CA 1322628 A DE 68900929 D GR 90300138 T GR 3003987 T JP 2174859 A JP 2680901 B US 5195984 A US 5902332 A ZA 8907357 A	15-03-1992 14-05-1992 12-04-1990 15-05-1990 05-10-1993 09-04-1992 27-09-1991 16-03-1993 06-07-1990 19-11-1997 23-03-1993 11-05-1999 31-10-1990
WO 9741916 A	13-11-1997	AU 2821597 A EP 0959933 A	26-11-1997 01-12-1999
US 5464395 A	07-11-1995	WO 9526776 A	12-10-1995
US 5102402 A	07-04-1992	CA 2077539 A DE 69119753 D DE 69119753 T EP 0519063 A IE 78821 B JP 5505132 T WO 9211890 A US 5370614 A US 5893840 A US 5324261 A	05-07-1992 27-06-1996 23-01-1997 23-12-1992 25-02-1998 05-08-1993 23-07-1992 06-12-1994 13-04-1999 28-06-1994
GB 2153235 A	21-08-1985	AU 575617 B AU 3819685 A BE 901611 A CA 1250235 A CH 670380 A DE 3503126 A FR 2558720 A GB 2187191 A,B GB 2187192 A,B IL 74180 A JP 1915610 C JP 6036817 B JP 61092672 A NL 8500239 A,B SE 464009 B SE 8500422 A US 5197977 A	04-08-1988 08-08-1985 17-05-1985 21-02-1989 15-06-1989 01-08-1985 02-08-1985 03-09-1987 03-09-1987 21-06-1992 23-03-1995 18-05-1994 10-05-1986 16-08-1985 25-02-1991 02-09-1985 30-03-1993